clinical trial · NCT07242781
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
Celgene·phase1·recruiting·n = 42
Healthy VolunteersBMS-986365ItraconazoleRifampin
brief summary
The purpose of this study is to evaluate the effect of Itraconazole and Rifampin on the drug levels of AR-LDD (BMS-986365) in healthy adult male participants.
started
Dec 15, 2025
primary completion
Jun 14, 2026
completion
Jun 14, 2026
last updated
Dec 24, 2025
official title
A Phase 1, Open-label, 2-part, Fixed-sequence, Crossover Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics of AR-LDD (BMS-986365) in Healthy Adult Male Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol